Title
Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys
Date Issued
24 August 2019
Access level
open access
Resource Type
journal article
Author(s)
Zhou B.
Danaei G.
Stevens G.A.
Bixby H.
Taddei C.
Solomon B.
Riley L.M.
Di Cesare M.
Iurilli M.L.C.
Rodriguez-Martinez A.
Zhu A.
Hajifathalian K.
Amuzu A.
Banegas J.R.
Bennett J.E.
Cameron C.
Cho Y.
Clarke J.
Craig C.L.
Cruz J.J.
Gates L.
Giampaoli S.
Gregg E.W.
Hardy R.
Hayes A.J.
Ikeda N.
Jackson R.T.
Jennings G.
Joffres M.
Khang Y.H.
Koskinen S.
Kuh D.
Kujala U.M.
Laatikainen T.
Lehtimäki T.
Lopez-Garcia E.
Lundqvist A.
Maggi S.
Magliano D.J.
Mann J.I.
McLean R.M.
McLean S.B.
Miller J.C.
Morgan K.
Neuhauser H.K.
Niiranen T.J.
Noale M.
Oh K.
Palmieri L.
Panza F.
Parnell W.R.
Peltonen M.
Raitakari O.
Rodríguez-Artalejo F.
Roy J.G.R.
Salomaa V.
Sarganas G.
Servais J.
Shaw J.E.
Shibuya K.
Solfrizzi V.
Stavreski B.
Tan E.J.
Turley M.L.
Vanuzzo D.
Viikari-Juntura E.
Weerasekera D.
Ezzati M.
Imperial College London
Publisher(s)
Elsevier B.V.
Abstract
Background: Antihypertensive medicines are effective in reducing adverse cardiovascular events. Our aim was to compare hypertension awareness, treatment, and control, and how they have changed over time, in high-income countries. Methods: We used data from people aged 40–79 years who participated in 123 national health examination surveys from 1976 to 2017 in 12 high-income countries: Australia, Canada, Finland, Germany, Ireland, Italy, Japan, New Zealand, South Korea, Spain, the UK, and the USA. We calculated the proportion of participants with hypertension, which was defined as systolic blood pressure of 140 mm Hg or more, or diastolic blood pressure of 90 mm Hg or more, or being on pharmacological treatment for hypertension, who were aware of their condition, who were treated, and whose hypertension was controlled (ie, lower than 140/90 mm Hg). Findings: Data from 526 336 participants were used in these analyses. In their most recent surveys, Canada, South Korea, Australia, and the UK had the lowest prevalence of hypertension, and Finland the highest. In the 1980s and early 1990s, treatment rates were at most 40% and control rates were less than 25% in most countries and age and sex groups. Over the time period assessed, hypertension awareness and treatment increased and control rate improved in all 12 countries, with South Korea and Germany experiencing the largest improvements. Most of the observed increase occurred in the 1990s and early-mid 2000s, having plateaued since in most countries. In their most recent surveys, Canada, Germany, South Korea, and the USA had the highest rates of awareness, treatment, and control, whereas Finland, Ireland, Japan, and Spain had the lowest. Even in the best performing countries, treatment coverage was at most 80% and control rates were less than 70%. Interpretation: Hypertension awareness, treatment, and control have improved substantially in high-income countries since the 1980s and 1990s. However, control rates have plateaued in the past decade, at levels lower than those in high-quality hypertension programmes. There is substantial variation across countries in the rates of hypertension awareness, treatment, and control. Funding: Wellcome Trust and WHO.
Start page
639
End page
651
Volume
394
Issue
10199
Language
English
OCDE Knowledge area
Sistema cardiaco, Sistema cardiovascular
Scopus EID
2-s2.0-85070928826
PubMed ID
Source
The Lancet
ISSN of the container
01406736
Sponsor(s)
Declaration of interests CC reports grants from Fitness Canada (government agency) during the conduct of the study, and grants from the Interprovincial Sport and Recreation Council, outside the submitted work. CLC reports grants from Fitness Canada (government agency) during the conduct of the study. RTJ reports grants from the National Heart Foundation of New Zealand and Health Research Council of New Zealand during the conduct of the study. DJM reports grants from Commonwealth Department of Health and Aged Care, Abbott Australasia Pty, Alphapharm Pty, AstraZeneca, Aventis Pharmaceutical, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Aust) Pty, GlaxoSmithKline, Janssen-Cilag (Aust) Pty, Merck Lipha, Merck Sharp & Dohme (Aust), Novartis Pharmaceutical (Aust) Pty, Novo Nordisk Pharmaceutical Pty, Pharmacia and Upjohn Pty, Pfizer Pty, Sanofi Synthelabo, Servier Laboratories (Aust) Pty, the Australian Kidney Foundation, and Diabetes Australia during the conduct of the study. JCM reports grants from Ministry of Health, New Zealand, during the conduct of the study. KS reports grants from Japan Ministry of Health, Labour and Welfare, and Ministry of Education, Culture, Sports, Science and Technology, during the conduct of the study. VSa reports grants from Finnish Foundation for Cardiovascular Research, personal fees and an honorarium for participating in an advisory board meeting from Novo Nordisk, and research collaboration that includes funding to affiliated institution from Bayer, outside the submitted work. JES reports grants from Commonwealth Department of Health and Aged Care, Abbott Australasia Pty, Alphapharm Pty, AstraZeneca, Aventis Pharmaceutical, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Aust) Pty, GlaxoSmithKline, Janssen-Cilag (Aust) Pty, Merck Lipha, Merck Sharp & Dohme (Aust), Novartis Pharmaceutical (Aust) Pty, Novo Nordisk Pharmaceutical Pty, Pharmacia and Upjohn Pty, Pfizer Pty, Sanofi Synthelabo, Servier Laboratories (Aust) Pty, the Australian Kidney Foundation, and Diabetes Australia during the conduct of the study. ME reports a charitable grant from the AstraZeneca Young Health Programme and personal fees from Prudential, Scor and Third Bridge outside the submitted work. All other authors declare no competing interests.
Sources of information: Directorio de Producción Científica Scopus